Skip to main content
. 2015 Jun 17;6(3):289–302. doi: 10.1007/s13300-015-0117-z

Fig. 5.

Fig. 5

Effects of canagliflozin on fasting plasma lipids (LOCF). CANA canagliflozin, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, LOCF last observation carried forward, LS least squares, PBO placebo, SE standard error. Asterisk Units of mol/mol for LDL-C/HDL-C